Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

Summary

The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis [UC]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Ulcerative Colitis
• Crohn Disease

Eligibility basics and study details

Study type

Interventional

Phase

Not applicable

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Mayo Clinic

Last updated on ClinicalTrials.gov

August 7, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites